FDA trial stocks are like the NCAA basketball tourney. Win and move on to next round or go home. No matter what the BMOD stock price does short term, BMOD and Cypath are moving on to the next round of trials and that makes them a winner today.
Here's your answer: Biomoda’s management team has determined that it makes sense to finish the optimization efforts, conducted both internally and in partnership with outstanding research and medical institutions, prior to launching the pivotal study. We expect that this will both improve the sensitivity and specificity of the assay and enhance Biomoda’s capability of successfully concluding the large-scale pivotal.